November 19, 2009 (FinancialWire) — IsoRay, Inc. (AMEX: ISR) said it has signed a distribution agreement with Inter V Medical of Montreal, Quebec, Canada. Under the deal, Inter V Medical will have exclusive rights to sell Cesium-131 Brachytherapy seeds in Canada, which have been previously approved by Health Canada.

Washington-based IsoRay is the sole producer of the Cesium-131 brachytherapy seed.

According to the company, the Cesium-131 seed offers a shorter radiation half-life than the two other isotopes commonly used for brachytherapy, which results in a faster delivery of therapeutic radiation, a theoretically improved radiation delivery against aggressively replicating cancer, and the potential for a reduced longevity of common brachytherapy side effects.

Cesium-131 is currently used in the treatment or prostate cancer and ocular melanoma, among other cancerous conditions.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.